No Data
No Data
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients a
Barinthus Bio Cuts 25% of Staff Amid Pipeline Shakeup
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $5
H.C. Wainwright analyst Yi Chen maintains $Barinthus Biotherapeutics(BRNS.US)$ with a buy rating, and adjusts the target price from $8 to $5.According to TipRanks data, the analyst has a success rate
Barclays Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $3
Barclays analyst Carter Gould maintains $Barinthus Biotherapeutics(BRNS.US)$ with a buy rating, and adjusts the target price from $7 to $3.According to TipRanks data, the analyst has a success rate of
Express News | Barinthus Biotherapeutics PLC : Barclays Cuts Target Price to $3 From $7
Barinthus Bio to Cut Workforce 25% to Focus on Hepatitis, Celiac Treatments After Positive Data; Shares Rise After Hours
Barinthus Biotherapeutics (BRNS) plans to cut 25% of its workforce to focus on development of VTP-300 for chronic Hepatitis B and VTP-1000 for celiac disease following positive interim data from trial
No Data